Company intelligence / Profile preview

NovaCina

Bentley, Western Australia, Australia

Ownership: Private
Employees: ~400
Development stage: Other

Overview

NovaCina was a leading CDMO specializing in sterile injectable pharmaceuticals with a 30+ year regulatory history and global approvals (FDA, TGA, ANVISA). Merged with BioCina in January 2025 to form a global end-to-end CDMO offering drug substance and sterile fill-finish drug product manufacturing, covering small molecules, biologics, microbial, plasmid DNA, and mRNA modalities, with rigorous quality and regulatory compliance.

Modalities: Small moleculeBiologicMicrobial drugPlasmid DNAmRNA-based drugs
Industry: Contract Manufacturing Organization

Partnerships

BioDuro-SundiaBio4t2

Beyond the preview

Go deeper on NovaCina.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovaCina.

Explore the full profile